Rabeprazole sodium + Esomeprazole
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Gastroesophageal Reflux Disease (GERD)
Conditions
Gastroesophageal Reflux Disease (GERD)
Trial Timeline
Feb 1, 2008 → Jan 1, 2010
NCT ID
NCT00658775About Rabeprazole sodium + Esomeprazole
Rabeprazole sodium + Esomeprazole is a phase 3 stage product being developed by Eisai for Gastroesophageal Reflux Disease (GERD). The current trial status is completed. This product is registered under clinical trial identifier NCT00658775. Target conditions include Gastroesophageal Reflux Disease (GERD).
What happened to similar drugs?
18 of 20 similar drugs in Gastroesophageal Reflux Disease (GERD) were approved
Approved (18) Terminated (2) Active (2)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00658775 | Phase 3 | Completed |
| NCT00658632 | Phase 3 | Completed |
| NCT00658528 | Phase 3 | Completed |
Competing Products
20 competing products in Gastroesophageal Reflux Disease (GERD)